Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) is a biotechnology company developing, manufacturing and seeking to commercialize genetic therapies for rare, often fatal diseases. Its programs use adeno-associated virus (AAV) vectors for in vivo gene delivery and lentiviral vectors to modify patients’ hematopoietic stem… From the company’s description.
Over the twelve months to Jun 30, 2026, Rocket Pharmaceuticals, Inc. reported a net loss of $17.25M. Operations used $170.27M in cash. In fiscal 2025, it reported a net loss of $223.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rocket Pharmaceuticals, Inc. does
In the company’s own words
Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) is a biotechnology company developing, manufacturing and seeking to commercialize genetic therapies for rare, often fatal diseases. Its programs use adeno-associated virus (AAV) vectors for in vivo gene delivery and lentiviral vectors to modify patients’ hematopoietic stem cells ex vivo. The pipeline focuses on inherited cardiovascular disorders, including Danon disease, PKP2-related arrhythmogenic cardiomyopathy and BAG3-related dilated cardiomyopathy, as well as hematologic diseases such as severe leukocyte adhesion deficiency-I. KRESLADI, an investigational therapy for leukocyte adhesion deficiency-I, is under FDA review following resubmission of its biologics license application. The company also develops therapies for Fanconi anemia and pyruvate kinase deficiency, though it has deprioritized those programs. Rocket operates a single reportable segment and has in-house research, development and manufacturing capabilities, including an approximately 100,000-square-foot U.S. AAV manufacturing facility. Its acquisition of Renovacor in 2022 added a gene therapy program for BAG3-related heart disease. Its website is https://www.rocketpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1281895
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rocket Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rocket Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rocket Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rocket Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rocket Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”